Extraordinary measures for clinical trials due to COVID-19

13 March 2020, Updated 02 April 2020

We have updated our guidance extraordinary measures for clinical trials due to COVID-19 to version 4.0.

Version 4.0 of this guidance includes the following updates:

  • Section 3 updated: Specified that remote source data verification (remote SDV) is not allowed in Denmark.
  • Section 4 updated: Opportunity to deliver IMP by Danish pharmacies added.
  • Section 5 updated: Section added regarding the use of qualified and trained personnel to administer the IMP and conducting other diagnostic tests at the study participant's residence.
  • Section 5 updated: Specified the importance of strengthened communication to trial participants during the COVID-19 pandemic.
We also include this version of the updated guidance with highlighted changes.

We are aware that COVID-19 has consequences with regards to the conduct of clinical trials in Denmark. Multiple factors play a role such as trial participants in quarantine, limited access to public places (including hospitals) due to the risk of spreading infections etc.

We prioritise all requests regarding COVID-19 and can be contacted per mail in case of questions related to clinical trials. Please mark any contacts clearly with ’COVID-19’ in the subject field. You can also contact our helpline (4488 9123).

The guidance regarding extraordinary measures for clinical trials due to COVID-19 will be updated continuously.

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.